---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-130478"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2023-12-29T23:59:59+00:00"
generated_at: "2026-06-07T05:59:03.550804+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Passage Bio settles derivative suit over director comp; to adopt new compensation policy, pay $390K fees

## Summary
- Stipulation filed Dec 13, 2023 resolves derivative action challenging 2020-2021 non-employee director compensation.
- Company agrees to adopt written Director Compensation Policy limiting annual pay to 62.5th percentile of peer group.
- Reforms include annual compensation consultant review, peer group market cap range, and enhanced proxy disclosures.
- Company to pay up to $390,000 in attorneys' fees and expenses to plaintiff's counsel; no admission of wrongdoing.
- Settlement hearing set for March 4, 2024; reforms to be maintained until at least Dec 31, 2027.

## SEC filing metadata
- accession: 0001104659-23-130478
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2023-12-29T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000110465923130478/0001104659-23-130478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000110465923130478/tm2333843d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-130478
- JSON: https://secwatch.observer/filing/0001104659-23-130478.json
- Plain text: https://secwatch.observer/filing/0001104659-23-130478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.